The article discusses the U.S. pharmaceutical company Perrigo's hostile takeover of the Irish biotechnology firm, Élan on December 18, 2013. Topics discussed include the total amount paid by Perrigo for the deal, Élan's rejection of the unsolicited takeover offer of Royalty Pharma, the hostile bid as a test for Ireland's Takeover Panel and Perrigo's use of an inversion structure in the acquisition deal.
© 2001-2025 Fundación Dialnet · Todos los derechos reservados